Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 1/2016

01-02-2016 | Original Article

Sesamin Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Inhibition of TLR4 Signaling Pathways

Authors: Li Qiang, Jiang Yuan, Jiang Shouyin, Li Yulin, Jiang Libing, Wang Jian-an

Published in: Inflammation | Issue 1/2016

Login to get access

Abstract

Recent studies suggested that TLR4 signaling pathways played an important role in the development of LPS-induced acute lung injury (ALI). Sesamin, a sesame lignan exacted from sesame seeds, has been shown to exhibit significant anti-inflammatory activity. The purpose of this study was to investigate the anti-inflammatory effects of sesamin on LPS-induced ALI in mice. Mice ALI model was induced by intratracheal instillation of LPS. Sesamin was given 1 h after LPS challenge. Our results showed that sesamin inhibited LPS-induced lung pathological change, edema, and myeloperoxidase (MPO) activity. Sesamin suppressed LPS-induced inflammatory cytokines TNF-α, IL-6, and IL-1β production. Furthermore, sesamin inhibited LPS-induced TLR4 expression and NF-κB activation. In conclusion, the results of this study indicated that sesamin protected against LPS-induced ALI by inhibition of TLR4 signaling pathways.
Literature
1.
Abraham, E., M.A. Matthay, C.A. Dinarello, J.L. Vincent, J. Cohen, S.M. Opal, M. Glauser, P. Parsons, C.J. Fisher Jr., and J.E. Repine. 2000. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Critical Care Medicine 28: 232–235.CrossRefPubMed
2.
Enkhbaatar, P., and D.L. Traber. 2004. Pathophysiology of acute lung injury in combined burn and smoke inhalation injury. Clinical Science (London) 107: 137–143.CrossRef
3.
Mei, S.H., S.D. McCarter, Y. Deng, C.H. Parker, W.C. Liles, and D.J. Stewart. 2007. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Medicine 4: e269.PubMedCentralCrossRefPubMed
4.
Joh, E.H., W. Gu, and D.H. Kim. 2012. Echinocystic acid ameliorates lung inflammation in mice and alveolar macrophages by inhibiting the binding of LPS to TLR4 in NF-kappaB and MAPK pathways. Biochemical Pharmacology 84: 331–340.CrossRefPubMed
5.
Piazza, M., V. Calabrese, C. Baruffa, T. Gioannini, J. Weiss, and F. Peri. 2010. The cationic amphiphile 3,4-bis(tetradecyloxy)benzylamine inhibits LPS signaling by competing with endotoxin for CD14 binding. Biochemical Pharmacology 80: 2050–2056.PubMedCentralCrossRefPubMed
6.
Sun, Y., Y. Zhao, J. Yao, L. Zhao, Z. Wu, Y. Wang, D. Pan, H. Miao, Q. Guo, and N. Lu. 2015. Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-kappaB and NLRP3 inflammasome activation. Biochemical Pharmacology 94: 142–154.CrossRefPubMed
7.
Kolb, M., P.J. Margetts, D.C. Anthony, F. Pitossi, and J. Gauldie. 2001. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. The Journal of Clinical Investigation 107: 1529–1536.PubMedCentralCrossRefPubMed
8.
Imai, Y., K. Kuba, G.G. Neely, R. Yaghubian-Malhami, T. Perkmann, G. van Loo, M. Ermolaeva, R. Veldhuizen, Y.H.C. Leung, H.L. Wang, et al. 2008. Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133: 235–249.CrossRefPubMed
9.
Ma, L., X. Gong, G. Kuang, R. Jiang, R. Chen, and J. Wan. 2015. Sesamin ameliorates lipopolysaccharide/d-galactosamine-induced fulminant hepatic failure by suppression of Toll-like receptor 4 signaling in mice. Biochemical and Biophysical Research Communications 461: 230–236.CrossRefPubMed
10.
Lv, H., C. Zhu, Y. Liao, Y. Gao, G. Lu, W. Zhong, Y. Zheng, W. Chen, and X. Ci. 2015. Tenuigenin ameliorates acute lung injury by inhibiting NF-kappaB and MAPK signalling pathways. Respiratory Physiology & Neurobiology 216: 43–51.CrossRef
11.
Jung, W.K., D.Y. Lee, J.H. Kim, I. Choi, S.G. Park, S.K. Seo, S.W. Lee, C.M. Lee, Y.M. Park, Y.J. Jeon, et al. 2008. Anti-inflammatory activity of caffeic acid phenethyl ester (CAPE) extracted from Rhodiola sacra against lipopolysaccharide-induced inflammatory responses in mice. Process Biochemistry 43: 783–787.CrossRef
12.
Xu, J., J. Qu, L. Cao, Y. Sai, C. Chen, L. He, and L. Yu. 2008. Mesenchymal stem cell-based angiopoietin-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice. Journal of Pathology 214: 472–481.CrossRefPubMed
13.
Liu, S., G. Feng, G.L. Wang, and G.J. Liu. 2008. p38MAPK inhibition attenuates LPS-induced acute lung injury involvement of NF-kappaB pathway. European Journal of Pharmacology 584: 159–165.CrossRefPubMed
14.
Reutershan, J., I. Vollmer, S. Stark, R. Wagner, K.C. Ngamsri, and H.K. Eltzschig. 2009. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. The Faseb Journal 23: 473–482.CrossRefPubMed
15.
Peng, X.Q., P.M. Hassoun, S. Sammani, B.J. McVerry, M.J. Burne, H. Rabb, D. Pearse, R.M. Tuder, and J.G.N. Garcia. 2004. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. American Journal of Respiratory and Critical Care Medicine 169: 1245–1251.CrossRefPubMed
16.
Kuebler, W.M., C. Abels, L. Schuerer, and A.E. Goetz. 1996. Measurement of neutrophil content in brain and lung tissue by a modified myeloperoxidase assay. International Journal of Microcirculation, Clinical and Experimental 16: 89–97.CrossRefPubMed
17.
Jiang, C., A.T. Ting, and B. Seed. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391: 82–86.CrossRefPubMed
18.
Strieter, R.M., J.A. Belperio, and M.P. Keane. 2002. Cytokines in innate host defense in the lung. The Journal of Clinical Investigation 109: 699–705.PubMedCentralCrossRefPubMed
19.
Chaluvadi, M.R., B.A. Nyagode, R.D. Kinloch, and E.T. Morgan. 2009. TLR4-dependent and -independent regulation of hepatic cytochrome P450 in mice with chemically induced inflammatory bowel disease. Biochemical Pharmacology 77: 464–471.PubMedCentralCrossRefPubMed
20.
Youn, H.S., J.K. Lee, Y.J. Choi, S.I. Saitoh, K. Miyake, D.H. Hwang, and J.Y. Lee. 2008. Cinnamaldehyde suppresses toll-like receptor 4 activation mediated through the inhibition of receptor oligomerization. Biochemical Pharmacology 75: 494–502.CrossRefPubMed
21.
Hung, L.C., C.C. Lin, S.K. Hung, B.C. Wu, M.D. Jan, S.H. Liou, and S.L. Fu. 2007. A synthetic analog of alpha-galactosylceramide induces macrophage activation via the TLR4-signaling pathways. Biochemical Pharmacology 73: 1957–1970.CrossRefPubMed
22.
Lin, M.W., L.T. Tsao, L.C. Chang, Y.L. Chen, L.J. Huang, S.C. Kuo, C.C. Tzeng, M.R. Lee, and J.P. Wang. 2007. Inhibition of lipopolysaccharide-stimulated NO production by a novel synthetic compound CYL-4d in RAW 264.7 macrophages involving the blockade of MEK4/JNK/AP-1 pathway. Biochemical Pharmacology 73: 1796–1806.CrossRefPubMed
23.
Youn, H.S., J.Y. Lee, S.I. Saitoh, K. Miyake, K.W. Kang, Y.J. Choi, and D.H. Hwang. 2006. Suppression of MyD88- and TRIF-dependent signaling pathways of toll-like receptor by (−)-epigallocatechin-3-gallate, a polyphenol component of green tea. Biochemical Pharmacology 72: 850–859.CrossRefPubMed
Metadata
Title
Sesamin Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Inhibition of TLR4 Signaling Pathways
Authors
Li Qiang
Jiang Yuan
Jiang Shouyin
Li Yulin
Jiang Libing
Wang Jian-an
Publication date
01-02-2016
Publisher
Springer US
Published in
Inflammation / Issue 1/2016
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-015-0270-6

Other articles of this Issue 1/2016

Inflammation 1/2016 Go to the issue

OriginalPaper

Etomidate Mitigates Lipopolysaccharide-Induced CD14 and TREM-1 Expression, NF-κB Activation, and Pro-inflammatory Cytokine Production in Rat Macrophages

OriginalPaper

Veratric Acid Inhibits LPS-Induced IL-6 and IL-8 Production in Human Gingival Fibroblasts

OriginalPaper

Icariin Attenuates High-cholesterol Diet Induced Atherosclerosis in Rats by Inhibition of Inflammatory Response and p38 MAPK Signaling Pathway

Original Article

Toxoplasma gondii Infection Promotes Neuroinflammation Through Cytokine Networks and Induced Hyperalgesia in BALB/c Mice

OriginalPaper

Role of Suppressor of Cytokine Signaling 3 in the Immune Modulation of Mesenchymal Stromal Cells

Original Article

No Association Between −159C/T Polymorphism of the CD14 Gene and Asthma Risk: a Meta-Analysis of 36 Case-Control Studies
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits